Keeping antibiotics working — for the patients who have run out of options, and for the medicine of the future that depends on them.
To transform the future of infectious disease treatment by discovering and developing breakthrough antibiotic therapies that overcome antimicrobial resistance.
Through world-class science, global collaboration, and unwavering innovation, Fedora Pharmaceuticals Inc. is committed to delivering life-saving medicines that address the world's most urgent unmet clinical needs — and safeguard global health for generations to come.
A team behind two globally marketed antibiotics — tazobactam and nacubactam — now taking on the resistance mechanisms the rest of the industry walked away from.
Partnering across pharma, biotech, academia, and government to move new anti-infectives out of the lab and into the patients who need them.
Pursuing genuinely new chemical classes — like the first clinical candidate from the lactivicin family — against the world's highest-priority pathogens.
From the AMR crisis to the pipeline advancing against it — explore the science driving Fedora forward.
